Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma

Area of Science:

• Oncology
• Immunology
• Clinical Pathology

Background:

• Absolute lymphocyte count (ALC) is a routine laboratory test in Merkel cell carcinoma (MCC) patient workups.
• ALC serves as a potential indicator of immune status in cancer patients.

Purpose of the Study:

• To investigate the prognostic significance of ALC in patients diagnosed with Merkel cell carcinoma (MCC).
• To evaluate ALC as a surrogate marker for immune status in the context of MCC.

Main Methods:

• Retrospective analysis of complete blood cell counts from 64 MCC patients prior to treatment.
• Statistical methods included classification and regression tree analysis, log rank test, and Cox proportional hazards models.

Main Results:

• Patients with ALC ≥ 1.1 k/mm³ had significantly longer median overall survival (110.1 months) compared to those with ALC < 1.1 k/mm³ (18.8 months).
• Multivariate analysis confirmed ALC as an independent prognostic factor for overall survival (P = .03).
• While a trend was observed, ALC did not significantly predict disease-free survival on multivariate analysis (P = .12).

Conclusions:

• Absolute lymphocyte count (ALC) is associated with overall survival in Merkel cell carcinoma (MCC).
• The threshold of 1.1 k/mm³ for ALC may offer additional prognostic information for MCC patients.
• Further research is needed to validate these findings in larger, multi-institutional cohorts.